According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Subscribe To Our Newsletter & Stay Updated
